US OptionsDetailed Quotes
OLMA241220P12500
- 2.15
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
2.15Open2.15Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover0.00%IV-69.67%PremiumDec 20, 2024Expiry Date6.40Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.90Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Olema Pharmaceuticals Stock Discussion
From past trends, December tends to be when the stock price takes a dive as investors are looking at other more dynamic stocks to invest in. Feb and Jul seems to be when the stock price tends to get an uplift. The drop off is especially drastic this Dec given the significant interest in all things crypto, Trump and AI related after the recent election.
There's been generally good news from Olem...
Olema set for an operatic debut at last | ApexOnco - Clinical Trials news and analysis
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
Olema Oncology announced updated clinical results for palazestrant combined with ribociclib in treating ER+/HER2- advanced or metastatic breast cancer. With a 12-month median follow-up, the study showed promising results with median progression-free survival (PFS) not yet reached. The 6-month PFS rate was 73% overall, wit...
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination With Ribociclib at the San Antonio Breast Cancer Symposium
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
Olema Pharmaceuticals (Nasdaq: OLMA) announced FDA clearance of its Investigational New Drug (IND) application for OP-3136, a novel small molecule that inhibits KAT6, an epigenetic target involved in breast and other cancers. The company plans to initiate a Phase 1 clinical trial in early 2025. OP-3136 has shown promising preclinical activity ...
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement With Novartis in Frontline Metastatic Breast Cancer as Well as $250 Million Equity Private Placement
Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024
Poster Details
Title:A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patients with estrogen receptor-positive, human epidermal gr...
No comment yet